February 5, 2025 at 11 a.m.
The Next Generation of Cancer Treatments
Dana-Farber Cancer Institute researchers have contributed to more than half of all FDA-approved cancer drugs in the last five years – including two this year: Ojemba for pediatric gliomas and Revumenib for leukemia. Still, many cancers remain hard to treat. Our physician-scientists are leading the way in developing next-generation therapies to bring hope to pediatric and adult patients worldwide.
Join Scott Armstrong, MD, PhD, Alice Shaw, MD, PhD, and Emily Heikamp, MD, PhD, MSc, as they delve into Dana-Farber's efforts to revolutionize cancer therapy, with a specific focus on rare and hard-to-treat cancers. Discover how Dana-Farber's unique infrastructure and expertise helps to accelerate the translation of cutting-edge research from the lab to patients, offering new hope and redefining what’s possible in cancer care. Don’t miss this chance to hear insights on advancements poised to transform patient outcomes and the future of oncology.
A live Q&A session will follow the presentation.
